Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.

Nicolodi C, Groiss F, Kiselev O, Wolschek M, Seipelt J, Muster T.

Vaccine. 2019 Jun 19;37(28):3722-3729. doi: 10.1016/j.vaccine.2019.05.013. Epub 2019 May 30.

PMID:
31155415
2.

Semi-continuous anaerobic co-digestion of chicken litter with agricultural and food wastes: A case study on the effect of carbon/nitrogen ratio, substrates mixing ratio and organic loading.

Zahan Z, Georgiou S, Muster TH, Othman MZ.

Bioresour Technol. 2018 Dec;270:245-254. doi: 10.1016/j.biortech.2018.09.010. Epub 2018 Sep 3.

PMID:
30219576
3.

Anaerobic digestion/co-digestion kinetic potentials of different agro-industrial wastes: A comparative batch study for C/N optimisation.

Zahan Z, Othman MZ, Muster TH.

Waste Manag. 2018 Jan;71:663-674. doi: 10.1016/j.wasman.2017.08.014. Epub 2017 Aug 23.

PMID:
28843753
4.

Application of Victorian brown coal for removal of ammonium and organics from wastewater.

Nazari MA, Mohaddes F, Pramanik BK, Othman M, Muster T, Bhuiyan MA.

Environ Technol. 2018 Apr;39(8):1041-1051. doi: 10.1080/09593330.2017.1319424. Epub 2017 May 8.

PMID:
28468599
5.

Electrochemically-assisted ammonia recovery from wastewater using a floating electrode.

Muster TH, Jermakka J.

Water Sci Technol. 2017 Apr;75(7-8):1804-1811. doi: 10.2166/wst.2017.060.

PMID:
28452772
6.

Application of a novel sampling bailer device for the analysis of dissolved methane concentrations in municipal wastewater during and following anaerobic treatment.

Beale DJ, Muster TH, Low J, Trickey M.

Water Sci Technol. 2016;73(12):2936-43. doi: 10.2166/wst.2016.150.

PMID:
27332839
7.

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Nov 12;10(11):e0143269. doi: 10.1371/journal.pone.0143269. eCollection 2015. No abstract available.

8.

An 'omics' approach towards the characterisation of laboratory scale anaerobic digesters treating municipal sewage sludge.

Beale DJ, Karpe AV, McLeod JD, Gondalia SV, Muster TH, Othman MZ, Palombo EA, Joshi D.

Water Res. 2016 Jan 1;88:346-357. doi: 10.1016/j.watres.2015.10.029. Epub 2015 Oct 27.

PMID:
26512813
9.

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Sep 18;10(9):e0138722. doi: 10.1371/journal.pone.0138722. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0143269.

10.

A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.

Kittel C, Wressnigg N, Shurygina AP, Wolschek M, Stukova M, Romanovskaya-Romanko E, Romanova J, Kiselev O, Muster T, Egorov A.

Arch Virol. 2015 Oct;160(10):2525-34. doi: 10.1007/s00705-015-2525-9. Epub 2015 Jul 28.

PMID:
26215439
11.

Enhanced efficiency fertilisers: a review of formulation and nutrient release patterns.

Timilsena YP, Adhikari R, Casey P, Muster T, Gill H, Adhikari B.

J Sci Food Agric. 2015 Apr;95(6):1131-42. doi: 10.1002/jsfa.6812. Epub 2014 Aug 12. Review.

PMID:
25043832
12.

Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography.

Banjac M, Roethl E, Gelhart F, Kramberger P, Jarc BL, Jarc M, Strancar A, Muster T, Peterka M.

Vaccine. 2014 May 1;32(21):2487-92. doi: 10.1016/j.vaccine.2014.02.086. Epub 2014 Mar 12.

PMID:
24631091
13.

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.

Morokutti A, Muster T, Ferko B.

Vaccine. 2014 Apr 7;32(17):1897-900. doi: 10.1016/j.vaccine.2014.02.009. Epub 2014 Feb 22.

PMID:
24560674
14.

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.

Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR.

Biotechnol J. 2014 Mar;9(3):405-14. doi: 10.1002/biot.201300225. Epub 2013 Dec 10. Erratum in: Biotechnol J. 2014 Apr;9(4):585.

PMID:
24323790
15.

Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.

Mössler C, Groiss F, Wolzt M, Wolschek M, Seipelt J, Muster T.

Vaccine. 2013 Dec 16;31(52):6194-200. doi: 10.1016/j.vaccine.2013.10.061. Epub 2013 Oct 30.

PMID:
24183981
16.

Photoluminescence enhancement of carbon dots by gold nanoparticles conjugated via PAMAM dendrimers.

Zong J, Yang X, Trinchi A, Hardin S, Cole I, Zhu Y, Li C, Muster T, Wei G.

Nanoscale. 2013 Nov 21;5(22):11200-6. doi: 10.1039/c3nr02527f. Epub 2013 Oct 1.

PMID:
24080833
17.

Carbon dots as fluorescent probes for "off-on" detection of Cu2+ and L-cysteine in aqueous solution.

Zong J, Yang X, Trinchi A, Hardin S, Cole I, Zhu Y, Li C, Muster T, Wei G.

Biosens Bioelectron. 2014 Jan 15;51:330-5. doi: 10.1016/j.bios.2013.07.042. Epub 2013 Jul 29.

PMID:
23994615
18.

Towards effective phosphorus recycling from wastewater: quantity and quality.

Muster TH, Douglas GB, Sherman N, Seeber A, Wright N, Güzükara Y.

Chemosphere. 2013 Apr;91(5):676-84. doi: 10.1016/j.chemosphere.2013.01.057. Epub 2013 Feb 28.

PMID:
23453605
19.

Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response.

Morokutti A, Redlberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N, Jungbauer A, Romanova J, Muster T, Popow-Kraupp T, Ferko B.

J Clin Virol. 2013 Apr;56(4):323-30. doi: 10.1016/j.jcv.2012.12.002. Epub 2013 Jan 31.

PMID:
23375739
20.

Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice.

Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, Song M, Czerkinsky C, Nguyen HH.

PLoS One. 2012;7(6):e39921. doi: 10.1371/journal.pone.0039921. Epub 2012 Jun 27.

21.

Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame.

van Rikxoort M, Michaelis M, Wolschek M, Muster T, Egorov A, Seipelt J, Doerr HW, Cinatl J Jr.

PLoS One. 2012;7(5):e36506. doi: 10.1371/journal.pone.0036506. Epub 2012 May 1.

22.

[Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].

Romanovskaia-Roman'ko EA, Ferko B, Vyshemirskiĭ OI, Romanova IuR, Krenn B, Muster T, Grudinin MP, Lapin BA, Egorov AIu, Kiselev OI.

Vopr Virusol. 2011 Nov-Dec;56(6):19-22. Russian.

PMID:
22359944
23.

Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture.

Roethl E, Gassner M, Krenn BM, Romanovskaya-Romanko EA, Seper H, Romanova J, Nakowitsch S, Sturlan S, Wolschek M, Sirotkin A, Kiselev O, Muster T, Egorov A.

J Virol. 2011 Nov;85(21):11139-45. doi: 10.1128/JVI.00169-11. Epub 2011 Aug 17.

24.

Expression of human endogenous retrovirus K is stimulated by ultraviolet radiation in melanoma.

Schanab O, Humer J, Gleiss A, Mikula M, Sturlan S, Grunt S, Okamoto I, Muster T, Pehamberger H, Waltenberger A.

Pigment Cell Melanoma Res. 2011 Aug;24(4):656-65. doi: 10.1111/j.1755-148X.2011.00860.x. Epub 2011 Jun 6.

PMID:
21501418
25.

Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.

Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, Ruthsatz T, Kiefmann B, Morokutti A, Humer J, Geiler J, Cinatl J, Michaelis M, Wressnigg N, Sturlan S, Ferko B, Batishchev OV, Indenbom AV, Zhu R, Kastner M, Hinterdorfer P, Kiselev O, Muster T, Romanova J.

PLoS One. 2011 Apr 7;6(4):e18577. doi: 10.1371/journal.pone.0018577.

26.

Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.

Nakowitsch S, Wolschek M, Morokutti A, Ruthsatz T, Krenn BM, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J.

Vaccine. 2011 Apr 27;29(19):3517-24. doi: 10.1016/j.vaccine.2011.02.100. Epub 2011 Mar 12.

PMID:
21406268
27.

Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency.

Wolschek M, Samm E, Seper H, Sturlan S, Kuznetsova I, Schwager C, Khassidov A, Kittel C, Muster T, Egorov A, Bergmann M.

J Virol. 2011 Mar;85(5):2469-73. doi: 10.1128/JVI.01650-10. Epub 2010 Dec 22.

28.

Pre-clinical safety evaluation of pyrrolidine dithiocarbamate.

Chabicovsky M, Prieschl-Grassauer E, Seipelt J, Muster T, Szolar OH, Hebar A, Doblhoff-Dier O.

Basic Clin Pharmacol Toxicol. 2010 Sep;107(3):758-67. doi: 10.1111/j.1742-7843.2010.00573.x. Epub 2010 Apr 12.

29.

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T.

J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428.

PMID:
20039806
30.

Electron-beam-induced carbon contamination on silicon: characterization using Raman spectroscopy and atomic force microscopy.

Lau D, Hughes AE, Muster TH, Davis TJ, Glenn AM.

Microsc Microanal. 2010 Feb;16(1):13-20. doi: 10.1017/S1431927609991206. Epub 2009 Dec 24.

PMID:
20030911
31.

Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells.

Ogbomo H, Michaelis M, Geiler J, van Rikxoort M, Muster T, Egorov A, Doerr HW, Cinatl J Jr.

Med Microbiol Immunol. 2010 May;199(2):93-101. doi: 10.1007/s00430-009-0139-0. Epub 2009 Dec 15.

PMID:
20012989
32.

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A.

PLoS One. 2009 Jun 19;4(6):e5984. doi: 10.1371/journal.pone.0005984.

33.

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

Wressnigg N, Voss D, Wolff T, Romanova J, Ruthsatz T, Mayerhofer I, Reiter M, Nakowitsch S, Humer J, Morokutti A, Muster T, Egorov A, Kittel C.

Vaccine. 2009 May 11;27(21):2851-7. doi: 10.1016/j.vaccine.2009.02.087. Epub 2009 Mar 11.

PMID:
19366569
34.

Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice.

Wressnigg N, Shurygina AP, Wolff T, Redlberger-Fritz M, Popow-Kraupp T, Muster T, Egorov A, Kittel C.

J Gen Virol. 2009 Feb;90(Pt 2):366-74. doi: 10.1099/vir.0.006122-0.

PMID:
19141445
35.

Azidothymidine inhibits melanoma cell growth in vitro and in vivo.

Humer J, Ferko B, Waltenberger A, Rapberger R, Pehamberger H, Muster T.

Melanoma Res. 2008 Oct;18(5):314-21. doi: 10.1097/CMR.0b013e32830aaaa6.

PMID:
18781129
36.

Sequence variability of retroviral particles derived from human melanoma cells melanoma-associated retrovirus.

Hirschl S, Schanab O, Seppele H, Waltenberger A, Humer J, Wolff K, Pehamberger H, Muster T.

Virus Res. 2007 Feb;123(2):211-5. Epub 2006 Sep 26.

PMID:
17005285
37.

Identification of a melanoma marker derived from melanoma-associated endogenous retroviruses.

Humer J, Waltenberger A, Grassauer A, Kurz M, Valencak J, Rapberger R, Hahn S, Löwer R, Wolff K, Bergmann M, Muster T, Mayer B, Pehamberger H.

Cancer Res. 2006 Feb 1;66(3):1658-63.

38.

Water adsorption kinetics and contact angles of pharmaceutical powders.

Muster TH, Prestidge CA.

J Pharm Sci. 2005 Apr;94(4):861-72.

PMID:
15736196
39.

Dynamic contact angle measurement on materials with an unknown wet perimeter.

Muster TH.

Int J Pharm. 2004 Sep 10;282(1-2):189-91.

PMID:
15336394
40.

Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants.

Muster T, Rajtarova J, Sachet M, Unger H, Fleischhacker R, Romirer I, Grassauer A, Url A, García-Sastre A, Wolff K, Pehamberger H, Bergmann M.

Int J Cancer. 2004 May 20;110(1):15-21.

41.

An endogenous retrovirus derived from human melanoma cells.

Muster T, Waltenberger A, Grassauer A, Hirschl S, Caucig P, Romirer I, Födinger D, Seppele H, Schanab O, Magin-Lachmann C, Löwer R, Jansen B, Pehamberger H, Wolff K.

Cancer Res. 2003 Dec 15;63(24):8735-41.

42.

Face specific surface properties of pharmaceutical crystals.

Muster TH, Prestidge CA.

J Pharm Sci. 2002 Jun;91(6):1432-44.

PMID:
12115843
43.
44.

Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis.

Salvatore M, Basler CF, Parisien JP, Horvath CM, Bourmakina S, Zheng H, Muster T, Palese P, García-Sastre A.

J Virol. 2002 Feb;76(3):1206-12.

45.

A genetically engineered influenza A virus with ras-dependent oncolytic properties.

Bergmann M, Romirer I, Sachet M, Fleischhacker R, García-Sastre A, Palese P, Wolff K, Pehamberger H, Jakesz R, Muster T.

Cancer Res. 2001 Nov 15;61(22):8188-93.

46.

Differential expression levels of Par-4 in melanoma.

Lucas T, Pratscher B, Krishnan S, Fink D, Günsberg P, Wolschek M, Wacheck V, Muster T, Romirer I, Wolff K, Pehamberger H, Eichler HG, Rangnekar VM, Jansen B.

Melanoma Res. 2001 Aug;11(4):379-83.

PMID:
11479426
47.

Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Wang X, Li M, Zheng H, Muster T, Palese P, Beg AA, García-Sastre A.

J Virol. 2000 Dec;74(24):11566-73.

48.

Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein.

Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, García-Sastre A.

J Virol. 2000 Sep;74(17):7989-96.

49.

Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication.

Bergmann M, Garcia-Sastre A, Carnero E, Pehamberger H, Wolff K, Palese P, Muster T.

J Virol. 2000 Jul;74(13):6203-6.

50.

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, García-Sastre A, Palese P.

Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14.

Supplemental Content

Loading ...
Support Center